Article Details

Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects

Retrieved on: 2023-12-01 21:22:47

Tags for this article:

Click the tags to see associated articles and topics

Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects. View article details on hiswai:

Excerpt

Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in the first half of 2024.

Article found on: www.cnbc.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo